PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity (Q44086502)

29 November 2017

title

PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity (English)

1 reference

29 November 2017

0 references

1 reference

acute myeloid leukemia

1 reference

Qian Ding

1

1 reference

29 November 2017

Ran Gu

2

1 reference

29 November 2017

Jiayi Liang

3

1 reference

29 November 2017

Xiangzhong Zhang

4

1 reference

29 November 2017

Yunxian Chen

5

1 reference

29 November 2017

publication date

19 January 2013

1 reference

29 November 2017

1 reference

29 November 2017

volume

30

1 reference

29 November 2017

issue

1

1 reference

29 November 2017

page(s)

395

1 reference

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Biology of normal and acute myeloid leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Drug therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Acute myeloid leukemia: epidemiology and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Cardiotoxicity of cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Anthracycline dose intensification in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Recent advances in acute myeloid leukemia stem cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0395-5

Acute leukaemia: development, remission/relapse pattern, relationship between normal and leukaemic haemopoiesis, and the 'sleeper-to-feeder' stem cell hypothesis.

21 January 2018

1 reference

12 December 2020

Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities

1 reference

12 December 2020

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia

1 reference

12 December 2020

Acute myelogenous leukemia

1 reference

12 December 2020

10.1007/S12032-012-0395-5

Identifiers

DOI

1 reference

29 November 2017

1 reference